-
COST-EFFECTIVENESS ANALYSIS OF RELMACABTAGENE AUTOLEUCEL VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL) WHO HAVE FAILED AT LEAST TWO LINES OF SYSTEMIC THERAPY IN CHINA
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION OF PULMONARY ARTERIAL HYPERTENSION USING REAL-WORLD EHR AND CLAIMS DATA
Mar 18, 2026, 21:38 PM -
COMPARISON OF POSTOPERATIVE ATRIAL FIBRILLATION, STROKE, MORTALITY, AND ECONOMIC OUTCOMES IN LOW-RISK TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PATIENTS: A SYSTEMATIC REVIEW USING THE PARTNER 3 TRIAL AS A COMPARATOR TO REAL-WORLD EVIDENCE
Mar 18, 2026, 21:38 PM -
DECLINING BASELINE HBA1C AT GLP-1 RECEPTOR AGONIST INITIATION IN U.S. ADULTS WITH TYPE 2 DIABETES, 2015-2024
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF DELAYED ACCESS TO FINERENONE DUE TO FORMULARY RESTRICTIONS IN CHRONIC KIDNEY DISEASE (CKD) AND TYPE 2 DIABETES (T2D)
Mar 18, 2026, 21:38 PM -
PARENTAL BURNOUT AMONG MOTHERS: THE ROLE OF COPING STYLES AND PSYCHOLOGICAL FACTORS
Mar 18, 2026, 21:38 PM -
FROM DELAYS TO DETERIORATION: A REVIEW OF THE IMPACT OF PRIOR AUTHORIZATION ON PATIENT HEALTH
Mar 18, 2026, 21:38 PM -
VALUE OF INFORMATION ANALYSIS FOR MANAGEMENT FOR INTERMITTENT CLAUDICATION: LLM-BASED RESULTS
Mar 18, 2026, 21:38 PM -
DEPRESSION AND HYPERTENSION AMONG U.S. ADULTS: A CROSS-SECTIONAL ANALYSIS OF NHANES DATA
Mar 18, 2026, 21:38 PM -
ADVANCING CANCER HEOR WITH A DECENTRALIZED, TRANSPARENT, AND INTERACTIVE OPEN SOURCE MODEL PLATFORM
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS VERSUS RAAS BLOCKERS IN SLOWING CKD PROGRESSION AMONG PATIENTS WITH DIABETIC NEPHROPATHY: INSIGHTS FROM REAL WORLD DATA
Mar 18, 2026, 21:38 PM -
FIRST-LINE CDK4/6 INHIBITOR USE IN METASTATIC BREAST CANCER: REAL-WORLD DATA FROM A RETROSPECTIVE US COHORT STUDY
Mar 18, 2026, 21:38 PM -
CORTICOSTEROID AND BIOLOGIC USE IN A REAL-WORLD POPULATION WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES AND GERMANY
Mar 18, 2026, 21:38 PM -
PSYCHOMETRIC EVALUATION OF SKINDEX-16 AA, THE ALOPECIA AREATA SYMPTOM IMPACT SCALE (AASIS), AND THE SCALP HAIR ASSESSMENT PATIENT-REPORTED OUTCOME (PRO) IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
Mar 18, 2026, 21:38 PM -
EVALUATING EARLY TREATMENT INITIATION REGIMES IN TREATMENT-RESISTANT DEPRESSION: A REINFORCEMENT LEARNING-BASED OFF-POLICY EVALUATION APPROACH
Mar 18, 2026, 21:38 PM -
?ECONOMIC IMPACT OF PET-18FLUTEMETAMOL GUIDED TREATMENT ALLOCATION IN THE DIAGNOSIS AND MANAGEMENT OF ALZHEIMER DISEASE. A BUDGET IMPACT MODEL FOR EUROPEAN PAYERS...
Mar 18, 2026, 21:38 PM -
PILOT EVALUATION OF AI-ENABLED AMBIENT SPEECH CAPTURE IN HOME-BASED CARE: REDUCING ADMINISTRATIVE BURDEN AND ENHANCING REAL-WORLD EVIDENCE GENERATION FOR COMPLEX THERAPIES
Mar 18, 2026, 21:38 PM -
100% WHEY PEPTIDE-BASED FORMULAS COMPARED TO POLYMERIC ENTERAL NUTRITION AMONG CHILDREN RECEIVING HOME ENTERAL NUTRITION: A COST-BENEFIT ANALYSIS
Mar 18, 2026, 21:38 PM -
A MULTI-AGENT GENERATIVE AI FRAMEWORK FOR AUTOMATED LANDSCAPE ASSESSMENTS IN RARE DISEASES: A CASE STUDY IN MULTIPLE SYSTEM ATROPHY
Mar 18, 2026, 21:38 PM -
APALUTAMIDE (APA) AS FIRST OPTION TO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) REPRESENTS COST-EFFECTIVE TREATMENT SEQUENCES TO HEALTH SYSTEMS
Mar 18, 2026, 21:38 PM
